Oncology Today—June 15, 2026

This week’s Oncology update highlights regulatory authorizations, clinical progress, pipeline expansion, enrollment milestones, and advancing precision medicine approaches across hematologic and solid tumor cancers.

In Today’s Newsletter

Dive deeper

💰 Johnson & Johnson to acquire Firefly Bio [1] [US • 08 Jun 2026]

https://www.investor.jnj.com/investor-news/news-details/2026/Johnson–Johnson-to-Acquire-Firefly-Bio-Inc–to-Expand-Oncology-Pipeline-with-Novel-Degrader-Antibody-Conjugate-Platform/default.aspx
Context: Johnson & Johnson entered a definitive agreement to acquire Firefly Bio for $1 billion in cash.
Key point: The deal adds Firefly Bio’s Firelink degrader antibody conjugate platform for KRAS-driven tumors.
Implication: Signals pipeline investment and modality expansion.

🧬 AIM ImmunoTech updates DURIPANC pancreatic cancer trial [2] [US • 08 Jun 2026]

https://aimimmuno.com/aim-immunotech-reports-positive-mid-year-interim-clinical-progress-from-phase-2-study-evaluating-ampligen-rintatolimod-in-combination-with-astrazenecas-imfinzi-durvalumab-for-the-tre/
Context: DURIPANC is evaluating Ampligen (rintatolimod) plus Imfinzi (durvalumab) in metastatic pancreatic cancer after FOLFIRINOX.
Key point: AIM reported positive mid-year interim clinical progress and remains on track for a Dec 2026 primary endpoint evaluation.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Amphista gets FDA IND clearance for AMX-883 [3] [UK, US • 08 Jun 2026]

https://amphista.com/amphista-therapeutics-announces-fda-clearance-of-ind-application-for-amx-883-its-lead-targeted-glue-degrader-for-acute-myeloid-leukaemia/
Context: AMX-883 is an oral DCAF16-dependent BRD9 degrader for relapsed or refractory AML and high-risk MDS.
Key point: FDA IND clearance enables a Phase 1 monotherapy dose-escalation and optimization trial planned for H2 2026.
Implication: Signals pipeline investment and modality expansion.

🛡️ Lyell reports LYL273 safety update in mCRC [4] [US • 08 Jun 2026]

https://ir.lyell.com/news-releases/news-release-details/lyell-immunopharma-provides-update-safety-profile-lyl273
Context: LYL273 is a GCC-targeted CAR T-cell therapy in relapsed or refractory metastatic colorectal cancer.
Key point: GI prophylaxis reduced Grade ≥2 diarrhea or colitis from 55% without prophylaxis to 10% with prophylaxis.
Implication: May influence prescriber choice and payer reviews pending full data.

✅ Roche Canada gains Lunsumio authorization [5] [Canada • 08 Jun 2026]

https://www.rochecanada.com/media/health-canada-authorizes-lunsumio-mosunetuzumab-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma-after-two-or-more-systemic-therapies
Context: Lunsumio (mosunetuzumab) targets CD20 and CD3 and is given for a fixed duration.
Key point: Health Canada authorized IV and SC formulations for adults with relapsed or refractory follicular lymphoma after at least two prior systemic therapies.
Implication: May expand treatment access and administration flexibility.

📊 Sumitomo reaches enzomenib enrollment milestone [6] [US, Japan • 10 Jun 2026]

https://news.us.sumitomo-pharma.com/press-release-details/2026/Sumitomo-Pharma-America-Achieves-Key-Patient-Enrollment-Milestone-for-Pivotal-Phase-2-Study-of-Enzomenib-in-the-Treatment-of-RelapsedRefractory-Acute-Leukemia/default.aspx
Context: Enzomenib (DSP-5336) is an investigational oral menin inhibitor for relapsed or refractory acute leukemia.
Key point: Sumitomo enrolled the required number of patients for interim analysis in KMT2A-rearranged acute leukemia.
Implication: May influence regulatory timelines if interim results support submission.

🏥 MAIA opens second US THIO-101 site [7] [US • 10 Jun 2026]

https://ir.maiabiotech.com/news-events/press-releases/detail/178/maia-biotechnology-activates-and-opens-enrollment-at-second
Context: THIO-101 evaluates ateganosine followed by cemiplimab in advanced NSCLC after prior checkpoint inhibitor treatment.
Key point: MAIA activated and opened enrollment at a second US clinical site in Alabama for the Phase 2 expansion trial.
Implication: May expand screening, initiation, and follow-up at scale.

📝 Ono files Opdivo label expansion in Japan [8] [Japan • 11 Jun 2026]

https://www.ono-pharma.com/ja/news/20260611.html
Context: The NAVIGATION Phase 2 trial evaluated Opdivo (nivolumab) plus Lenvima (lenvatinib) in unresectable anaplastic thyroid cancer.
Key point: Ono submitted a partial amendment application in Japan after the trial achieved objective response rate as the primary endpoint.
Implication: May influence prescriber choice and payer reviews pending regulatory review.

Why it matters

Protein degradation remains a major oncology investment theme, spanning J&J–Firefly, Amphista’s AMX-883, and broader targeted-degrader platforms.
Hematology pipelines advanced through regulatory authorization, IND clearance, and pivotal enrollment milestones.
Solid tumor cell therapy and immunotherapy programs are moving toward later-stage designs, broader enrollment, or label expansion.
Administration flexibility is becoming a competitive feature, as shown by Lunsumio IV and SC authorization in Canada.
Several updates are directional or interim, so full datasets and regulatory decisions remain the key next catalysts.

📚 Discover the full Oncology archive on our research hub page.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

FAQ

What is Johnson & Johnson buying from Firefly Bio?

Johnson & Johnson agreed to acquire Firefly Bio and its Firelink degrader antibody conjugate platform, focused on KRAS-driven tumors and other hard-to-treat cancers [1].

What is the next key timing for AIM ImmunoTech’s DURIPANC trial?

AIM said the Phase 2 study remains on track for a planned Dec 2026 primary endpoint evaluation. The endpoint is clinical benefit rate at 24 weeks [2].

What does FDA IND clearance mean for Amphista’s AMX-883?

It allows Amphista to start a Phase 1 trial of AMX-883 in relapsed or refractory AML and high-risk MDS, planned for H2 2026 [3].

What changed in Lyell’s LYL273 trial?

Lyell reported lower Grade ≥2 diarrhea or colitis with GI prophylaxis and amended the trial to a Phase 1/2 design that could expand into a pivotal single-arm Phase 2 trial, pending alignment [4].

What did Health Canada authorize for Roche Canada’s Lunsumio?

Health Canada authorized both IV and SC Lunsumio for adults with relapsed or refractory follicular lymphoma after at least two prior systemic therapies [5].

What is Ono seeking for Opdivo in Japan?

Ono submitted a partial amendment application to add unresectable anaplastic thyroid cancer, based on Opdivo plus Lenvima Phase 2 data [8].

Entities / Keywords

Johnson & Johnson, J&J, Firefly Bio, Firelink, degrader antibody conjugate, DAC, KRAS-driven tumors
AIM ImmunoTech, Ampligen, rintatolimod, Imfinzi, durvalumab, DURIPANC, metastatic pancreatic cancer
Amphista Therapeutics, AMX-883, Targeted Glue, BRD9 degrader, DCAF16, AML, MDS
Lyell Immunopharma, LYL273, GCC CAR T, CARABINER, metastatic colorectal cancer, mCRC
Roche Canada, Lunsumio, mosunetuzumab, follicular lymphoma, FL, IV, SC
Sumitomo Pharma America, enzomenib, DSP-5336, menin inhibitor, KMT2A rearrangement, NPM1 mutation
MAIA Biotechnology, ateganosine, THIO, THIO-101, cemiplimab, NSCLC
Ono Pharmaceutical, Opdivo, nivolumab, Lenvima, lenvatinib, NAVIGATION, anaplastic thyroid cancer